Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry

Eliglustat is a first‐line oral therapy for adults with Gaucher disease type 1 (GD1) with extensive, intermediate, or poor CYP2D6‐metabolizer phenotypes (90% of patients). We report real‐world outcomes after 2 years of eliglustat therapy in the International Collaborative Gaucher Group Gaucher Regis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, Pramod K., Balwani, Manisha, Charrow, Joel, Kishnani, Priya, Niederau, Claus, Underhill, Lisa H., McClain, Monica R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497238/
https://www.ncbi.nlm.nih.gov/pubmed/32438452
http://dx.doi.org/10.1002/ajh.25875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497238/
https://www.ncbi.nlm.nih.gov/pubmed/32438452
http://dx.doi.org/10.1002/ajh.25875

Ejemplares similares